Hosted on MSN1mon
Quantum BioPharma Stock Soars As Unbuzzd Trial Shows Rapid Fall In Blood Alcohol Levels, Retail Frenzy EnsuesThe rally comes after the company announced the completion of a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, Unbuzzd, for alcohol metabolism.
Quantum BioPharma announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial of its dietary supplement product unbuzzd, investigating its ...
Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover TORONTO, Feb. 04 ...
Hosted on MSN1mon
Quantum BioPharma Heads For Best Week Ever — But Most Retail Traders Lament Missing Out On The SurgeThe surge followed Tuesday's announcement that Quantum had completed a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, Unbuzzd, for alcohol metabolism.
The company is focused on promoting its innovative products, including unbuzzd™, a rapid alcohol detox beverage, and rekvry™, aimed at alcohol misuse treatment. CEO Zeeshan Saeed highlighted ...
Chris Tyson, Executive Vice President at MZ North America, commented, "unbuzzd™ and rekvry™ utilize revolutionary technology that address the issue of excessive alcohol use. The National ...
Results of data analysis show definitively that unbuzzd™ accelerated the rate at which Blood Alcohol Concentration (“BAC”) was reduced in study subjects, while simultaneously reducing the ...
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results